Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

MLA

Ascierto, Paolo Antonio, et al. “Dabrafenib, Trametinib and Pembrolizumab or Placebo in BRAF-Mutant Melanoma.” Nature Medicine, vol. 25, no. 6, June 2019, p. 941. EBSCOhost, https://doi.org/10.1038/s41591-019-0448-9.

APA

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., & Schachter, J. (2019). Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine, 25(6), 941. https://doi.org/10.1038/s41591-019-0448-9

Chicago

Ascierto, Paolo Antonio, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, and Jacob Schachter. 2019. “Dabrafenib, Trametinib and Pembrolizumab or Placebo in BRAF-Mutant Melanoma.” Nature Medicine 25 (6): 941. doi:10.1038/s41591-019-0448-9.